Burosumab’s pediatric phase 2 studies in X-linked hypophosphatemia yield positive results

This article was originally published here

Ultragenyx Pharmaceutical and Kyowa Kirin International (KKI), a subsidiary of Kyowa Hakko Kirin (Kyowa Hakko Kirin), have reported positive 64-week data from a pediatric Phase 2 study of burosumab (KRN23) for X-linked hypophosphatemia (XLH) treatment in children aged between five and 12 years.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply